Astrocyte Pharmaceuticals is currently investigating several programs for the potential treatment of acute ischemic stroke, TBI, concussion, and other injuries to the brain.

The company’s lead program AST-004 is a novel small molecule candidate currently in human Phase I clinical safety trials with an intravenous injection formulation suitable for administration by emergency professionals.  An oral “field” formulation of AST-004 for mild TBI and concussions, and for chronic administration for neurodegenerative diseases and migraine is in development.

Human Phase II patient clinical efficacy trials are being planned for next year, while subsequent Phase III studies, and New Drug Application (NDA) review by regulatory agencies such as the FDA typically take an additional 2-5 years to confirm results and approve use of a new therapeutic.


Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders